# Richard Bernstein Advisors

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/richard-bernstein-advisors
Canonical HTML page: https://getfinancebrief.com/entity/richard-bernstein-advisors

## Timeline

- **2026-03-12**: BofA Target Increase — Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
- **2026-03-10**: Institutional Rebalancing — Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
- **2026-03-07**: Fast-Track Approval — FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
- **2026-03-05**: FDA Approval & 12-Month High — JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.

## Recent coverage (1 stories)

### BofA Bullish on Johnson & Johnson as Pipeline Momentum Drives Target Hike
2026-03-12 08:12:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Full story: https://getfinancebrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.